A 5-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Safety, Tolerance & Pharmacokinetics Study of CI-1034 in Patients with Secondary Pulmonary Hypertension Associated with Cardiopumnary Disease